Ahmed Harb

Ahmed Harb

Auto-generated profile, based on publicly available information

Ahmed Harb

Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in ASIDE Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
PSPranjal Kumar Singh
Pranjal Kumar Singh
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
AHAhmed Harb
Ahmed Harb
SMSai Lokesh Moraboina
Sai Lokesh Moraboina
SCSanchit Shailendra Chouksey
Sanchit Shailendra Chouksey
Introduction: Posterior reversible encephalopathy syndrome (PRES) is a neurovascular disorder characterized by vasogenic edema, most often affecting the parieto-occipital lobes. Although typically reversible, some patients develop lasting neurological sequelae such as cognitive or visual impairment and epilepsy. This review summarizes the current understanding of PRES beyond its classical association with hypertension, emphasizing emerging triggers, mechanisms, and updates in management. Methods: A structured narrative review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) framework. Literature was systematically searched in PubMed, Web of Science, and Google Scholar for studies published between January 1996 and June 2025. Fifty-nine relevant publications, including original studies and reviews, were synthesized to integrate evidence on presentation, imaging, pathophysiology, genetics, and management. Results: PRES can be triggered by a broad spectrum of hypertensive and non-hypertensive conditions, such as renal dysfunction, eclampsia, systemic lupus erythematosus, sepsis, and exposure to immunosuppressive agents (e.g., tacrolimus, cyclosporine, rituximab). The syndrome involves multifactorial mechanisms, including endothelial dysfunction, blood–brain barrier disruption, and dysregulated cerebral autoregulation. Emerging data indicate that genetic polymorphisms in endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and aquaporin genes may influence individual susceptibility, although causality remains unconfirmed. Conclusion: PRES is a multifactorial syndrome that extends beyond hypertension. Early recognition, prompt neuroimaging, and targeted management of underlying triggers are critical for improving outcomes. Future studies should focus on clarifying genetic associations, standardizing diagnostic criteria for atypical cases, and optimizing therapeutic strategies through personalized medicine approaches.

19 October 2026 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
NMNada Mosad
Nada Mosad
YRYara Roshdy
Yara Roshdy
TETasbih Emad
Tasbih Emad
AHAhmed Harb
Ahmed Harb
DADina Essam Abo-Elnour
Dina Essam Abo-Elnour
AAAsmaa Zakria Alnajjar
Asmaa Zakria Alnajjar

16 September 2026 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
SNSandeep Samethadka Nayak
Sandeep Samethadka Nayak
ASAya Magdy Siam
Aya Magdy Siam
AAAbdullah Almarfadi
Abdullah Almarfadi
NANour Aldin T. Ahmed
Nour Aldin T. Ahmed
RHRoaa Haddad
Roaa Haddad
DKDavid F. Kallmes
David F. Kallmes

17 September 2026 in Asian Journal of Neurosurgery
Verified
Journal Article
Open access
AHAhmad Hamza
Ahmad Hamza
AHAhmed Harb
Ahmed Harb
NMNada Mosad
Nada Mosad
ANAsmaa Nasreldin
Asmaa Nasreldin
OAOmar F. Abbas
Omar F. Abbas
RKRam Kadirvel
Ram Kadirvel
Stroke thrombi are heterogeneous; their composition influences their mechanical properties, including stiffness, elasticity, and adhesiveness, which in turn affect their response to therapy. Systemic characterization of the thrombi components could help select therapeutic techniques and anticipate outcomes. We conducted a systematic review and meta-analysis to evaluate associations between thrombi composition and angiographic and functional outcomes in acute ischemic stroke (AIS). Up to May 2025, relevant studies were sourced from four databases: PubMed, Web of Science, Scopus, and Embase. We included cohort studies whose populations are patients with AIS in relation to thrombi composition. Thirty-six studies involving 5,462 patients matched our eligibility criteria. Angiographic success (Thrombolysis in Cerebral Infarction ≥ 2b/3) did not differ significantly between red blood cell (RBC)-rich and fibrin-rich thrombi (risk ratio [RR] 1.02, 95% confidence interval [CI] 0.85–1.22; p = 0.84; I 2 = 63.8%; very low certainty). However, thrombi from patients with good angiographic outcomes had a significantly higher RBC content compared to patients with poor outcomes (mean difference = 7.22%, 95% CI 3.31–11.13; p < 0.001; low certainty). No significant difference was observed between RBC-rich and fibrin-rich thrombi regarding functional independence at 90 days (modified Rankin Scale 0–2) (RR = 1.22, 95% CI 0.73–2.05; p = 0.31; low certainty). While RBC-rich thrombi are associated with more favorable angiographic performance, thrombus composition alone does not predict functional outcomes. Stroke outcomes remain multifactorial, dominated by time to reperfusion, collateral circulation, and baseline severity. Preinterventional assessment of clot composition via imaging or biomarkers may support individualized therapy but should complement, not replace, other prognostic determinants.

19 June 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
AMAhmed Hafez Mousa
Ahmed Hafez Mousa
GAGergis Altalab
Gergis Altalab
AMAnas Mansour
Anas Mansour
AHAhmed Harb
Ahmed Harb
SDSalma Daffa
Salma Daffa
BCBabacar Cisse
Babacar Cisse
Background Pituitary metastases (PM) are rare intracranial secondary tumors, most often arising from breast and lung primaries. They are clinically significant due to their association with advanced systemic malignancy and potential to cause visual, neurological, and endocrinological morbidity. Conventional therapies such as surgery and fractionated radiotherapy have limited efficacy or high morbidity. Stereotactic radiosurgery (SRS) has emerged as a minimally invasive alternative, but available evidence is limited to small, heterogeneous series. Objective To evaluate the effectiveness and safety of SRS in patients with PM by synthesizing data on tumor control, survival outcomes, progression-free survival (PFS), and treatment-related morbidity. Methods A systematic review and meta-analysis were performed according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched through June 2025. Eligible studies included patients with radiologically or histologically confirmed PM treated with SRS. Outcomes of interest were local tumor control, survival, PFS, radiological response, and complications, including hypopituitarism, optic neuropathy, and radiation necrosis. Data were pooled using a random-effects single-arm meta-analysis model. Results Six retrospective case series comprising 142 patients were included. Pooled local control following SRS was 89% (95% CI 75–96%). Six-month PFS was 97% (95% CI 83–100%). One- and two-year survival rates were 53% (95% CI 32–73%) and 40% (95% CI 15–72%), respectively. Tumor regression occurred in 34% and stable disease in 33%, while only 7% demonstrated progression. Treatment-related morbidity was low: new-onset hypopituitarism (1%), optic neuropathy (2%), and radiation necrosis (1%). Conclusion SRS provides effective and durable local control of pituitary metastases with a favorable safety profile and low rates of treatment-related toxicity. Despite the poor systemic prognosis associated with PM, SRS offers meaningful intracranial disease control and symptom relief, particularly in well-selected patients with stable systemic disease. Larger prospective, standardized studies are needed to further clarify long-term endocrine and neurological outcomes.